MAP2K7 and Alzheimer disease: Here, we tested the therapeutic efficacy of trametinib in 5XFAD mice that co-overexpress human amyloid precursor protein (APP) and presenilin 1 harboring five familial AD mutations [30] and explored the mechanisms of MEK inhibition in the Aβ-associated autophagic lysosomal activity.